繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 直肠癌/结肠癌 >> 药品推荐 >> Lonsurf combination tablet(Trifluridine Tipiracil Hydrochloride)

Lonsurf combination tablet(Trifluridine Tipiracil Hydrochloride)

2014-06-10 03:29:20  作者:新特药房  来源:互联网  浏览次数:1019  文字大小:【】【】【
简介: 英文药名:Lonsurf combination tablet(Trifluridine Tipiracil Hydrochloride) 中文药名:三氟胸苷和tipiracil盐酸盐片 日文药名:ロンサーフ配合錠 生产厂家:大鹏药品药品介绍:批准上市时间:20 ...

英文药名:Lonsurf combination tablet(Trifluridine Tipiracil Hydrochloride)

中文药名:三氟胸苷和tipiracil盐酸盐片

生产厂家:大鹏药品

ロンサーフ配合錠T15/ロンサーフ配合錠T20

治疗类别名称
抗肿瘤药
批准上市时间:2014年月
商標名
Lonsurf combination tablet T15
Lonsurf combination tablet T20
トリフルリジン
構造式

一般名
トリフルリジン(Trifluridine)
化学名
2'-Deoxy-5-(trifluoromethyl)uridine
分子式
C10H11F3N2O5
分子量
296.20
融点
約182℃(分解)
性状
它是一种白色晶体或结晶粉末。
易溶于甲醇,水和乙醇(99.5)微溶。
チピラシル塩酸塩
構造式

一般名
チピラシル塩酸塩(Tipiracil Hydrochloride)
化学名
5-Chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4 (1H,3H)-dione monohydrochloride
分子式
C9H11ClN4O2・HCl
分子量
279.12
融点
約241℃(分解)
性状
它是一种白色晶体或结晶粉末。
微溶于水,在甲醇中极微溶,并在乙醇(99.5)几乎不溶。
药效药理
1. 抗肿瘤作用
人的大肠癌细胞衍生COL-1细胞在裸鼠中线和HCT-116细胞系皮下植入,该药物表现出肿瘤生长的抑制作用。此外,在裸小鼠与人大肠癌细胞衍生KM20C的细胞系在腹腔被移植,药物呈存活益处。
2. 作用机理
肿瘤衍生的细胞系皮下植入,因为掺入DNA FTD的量和肿瘤生长抑制效果相关,这种药物的FTD,还了FTD的DNA的基础上的肿瘤增殖抑制效果估计由正在采取的肿瘤生长抑制效果被发挥。
此外,当在猴子口服FTD单独,虽然FTD基本上不血液中观察到的,FTD的血液浓度通过抑制TPase分解酶FTD TPI的组合保持。
适应病症:
不能手术切除,晚期或复发性结肠癌,直肠癌
用法与用量
成人以适合初始剂量(量一次)体表面积至下一参考量(约35毫克/平方米/剂量为三氟胸苷),早餐后和晚餐后,一天两次,连续5天其次是口服给药后停药两天。随后停药14天后此重复两次。重复给药,本为一疗程。
应当指出的是,根据该状态的患者减肥。
(见用法和剂量的表)
用法与用量的表

体表面積(m2  初回基準量
(トリフルリジン相当量
 
~1.07未満  35mg/回(70mg/日) 
1.07以上~1.23未満  40mg/回(80mg/日) 
1.23以上~1.38未満  45mg/回(90mg/日) 
1.38以上~1.53未満  50mg/回(100mg/日) 
1.53以上~1.69未満  55mg/回(110mg/日) 
1.69以上~1.84未満  60mg/回(120mg/日) 
1.84以上~1.99未満  65mg/回(130mg/日) 
1.99以上~2.15未満  70mg/回(140mg/日) 
2.15以上~  75mg/回(150mg/日) 
包装
组合片剂 T15
PTP包装:20片(10片×2),60片(10片×2×3)
组合片剂T20
PTP包装:20片(10片×2),60片(10片×2×3)


制造厂商
大鹏药业有限公司
完整处方附件:http://www.info.pmda.go.jp/go/pack/4299100F1026_1_03/
2014年3月24日,日本MHLW批准大鹏药业Taiho Pharma的TAS-102(曲氟胸苷+tipiracil),用于治疗不可切除型或复发型晚期结直肠癌。曲氟胸苷是一种核苷类抗癌药,干扰癌细胞DNA的合成,tipiracil是胸苷磷酸化酶抑制剂,减少曲氟胸苷的降解。


Taiho's Lonsurf®(trifluridine and tipiracil hydrochloride) Tablets Approved in Japanfor Treatment in Advanced me-tastatic Colorectal Cancer
Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi) announced today that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combinationanticancerdrug'Lonsurf®combination tablet T15, T20'' (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).
Japan is the first country in the world to grant marketing authorization for Lonsurf. The approval is based primarily on the results of a randomized, double blind placebo controlled Phase II clinical trial conducted in Japan(J003-10040030).
Taiho is conducting a global Phase III clinical trial(RECOURSE) on patients with me-tastatic colorectal cancer refractory to standard chemotherapies.
Lonsurf is a combination drug of trifluridine (FTD) and tipiracil hydrochloride(TPI). FTD is an antineoplastic nucleoside analog, which is incorporated directly into DNA, thereby interfering with the function of DNA.
The blood concentration of FTD is maintained via TPI, which is an inhibitor of the
FTD-degrading enzyme thymidine phosphorylase.
Taiho Pharmaceutical is proud to make Lonsurf available to physicians in Japan as a new treatment option for patients with me-tastatic colorectal cancer refractory to standard therapies.
Product Summary (for the Japanese market)Brand name
Lonsurf®combination tablet T15, T20
Nonproprietary name
Trifluridine and tipiracil hydrochloride combination tabletIndications & Efficacy
Unresectable advanced or recurrent colorectal cancer refractory to standard therapies
Use & Dosage
Usually, the initial dose (single dose) for adults is defined as the standard dose (approximately 35mg/m2/dose of FTD)according to body surface area.
Lonsurf is administered twice daily, after breakfast and after the evening meal, for five consecutive days, followed by a two-day rest. After repeating the above twice, a 14-day rest follows, completing one course, which is then repeated.
The dose can be decreased or increased according to the patient's condition.

责任编辑:admin


相关文章
TS-1 combination granule T20/T25(替吉奥混合颗粒)
TS-1 combination capsule T20/T25(替吉奥配合胶囊)
TS-1 combination OD tablet T20/T25(替吉奥配合口腔崩解片)
PROTECADIN OD tablet(拉呋替丁口腔崩解片)
PROTECADIN tablet(拉呋替丁片)
HYDRA TABLET(Isoniazid)异烟肼片
Kaletra Combination Tablets(洛匹那韦/利托那韦复方片)
NKS-1 combination granule T20/T25(复合替加氟/吉美嘧啶/氧嗪酸钾颗粒)
LOSARHYD Combination Tab LD/HD(复合氯沙坦钾/氢氯噻嗪LD/HD片)
EquMet Combination Tablets LD/HD(维达列汀/盐酸二甲双胍组合片)
贝前列素钠LA片|BERASUS LA Tablets(Beraprost sodium)
 

最新文章

更多

· ERBITUX Injection(西妥...
· 卡培他滨片|XELODA(cape...
· ISOVORIN INJECTION(Lev...
· 5-FU Injection(氟尿嘧...
· 雷莫芦单抗注射剂|CYRAM...
· AVASTIN Inf Konz(Beva...
· Futraful injection(替...
· KRESTIN Fine Granules(...
· LONSURF(trifluridine/t...
· UZEL tablet(Calcium f...

推荐文章

更多

· ERBITUX Injection(西妥...
· 卡培他滨片|XELODA(cape...
· ISOVORIN INJECTION(Lev...
· 5-FU Injection(氟尿嘧...
· 雷莫芦单抗注射剂|CYRAM...
· AVASTIN Inf Konz(Beva...
· Futraful injection(替...
· KRESTIN Fine Granules(...
· LONSURF(trifluridine/t...
· UZEL tablet(Calcium f...

热点文章

更多

· ERBITUX Injection(西妥...